policy

First Opinion By William Feehery and Julie Bullock

Three steps can help companies speed FDA approval of new drugs

Politics By Nicholas Florko

The questions Congress should ask Pfizer, Moderna, and Johnson & Johnson about the Covid-19 vaccines 

First Opinion By Aaron Siri

Federal law prohibits employers and others from requiring vaccination with a Covid-19 vaccine distributed under an EUA

Health Tech By Alicia Diaz

Federal watchdog raises concerns about increasing telehealth fraud during pandemic 

First Opinion By Lanhee J. Chen, Tom Church, and Daniel L. Heil

A public option for health insurance could be a disaster, especially in times of crisis

Politics By Rachel Cohrs

The Biden administration is making nursing schools pay for a government mistake amid Covid-19

First Opinion By William S. Smith

The Biden administration needs to look beyond ICER for evaluating drug therapies

Politics By Nicholas Florko

Woodcock vs. Sharfstein: A head-to-head comparison of Biden’s top choices for FDA commissioner 

Special Report By Rachel Cohrs

Hospitals’ Covid-19 heroics have them poised for power in the new Washington

First Opinion By Michelle A. Williams

Public health is being undermined. These 10 actions can restore it

Politics By Rachel Cohrs

Biden administration pumps brakes on signature Trump drug pricing proposal

First Opinion By Jakub Hlávka and Lisa Bari

Travel bans should be based on evidence, not politics or fear

Exclusive By Nicholas Florko and Lev Facher

Longtime Becerra aide and two health policy experts to be tapped for key posts

First Opinion By Jack Lienke

Azar’s ‘Sunset Rule’ will bring a dangerous new dawn for health regulation

Politics By Nicholas Florko, Lev Facher, Rachel Cohrs, Andrew Joseph, and Casey Ross

The 9 biggest challenges Biden will face on Covid-19, from today on

Politics By Nicholas Florko

Amid last minute changes and funding shortfalls, Biden adviser predicts a slow start to the ‘100 million vaccines in 100 days’ goal 

Exclusive By Lev Facher

Biden’s Covid-19 team reconsiders pandemic plan in light of more infectious coronavirus variants

Politics By Nicholas Florko and Lev Facher

Democrats have their best shot yet at letting Medicare negotiate drug prices — but it’s still not a done deal

Politics By Lev Facher

Biden’s appointment of a health disparities adviser is historic. But will the White House empower her?

Politics By Nicholas Florko

3 freshman lawmakers for health wonks to watch 

Politics By Lev Facher

Federal judge places restraining order on Trump’s latest drug pricing rule

Politics By Nicholas Florko

This tiny, one-drug biotech company is the loudest critic of Trump’s new international drug pricing policy

Politics By Lev Facher

Patrick Kennedy pitches himself for Biden ‘drug czar’

Politics By Nicholas Florko

3 reasons the drug industry should be worried about Biden’s HHS pick, Xavier Becerra

Politics By Lev Facher

Biden’s health picks signal a bottom-up approach to the Covid-19 pandemic